Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE

Reperfusion Paradox: The Hidden Threat in STEMI After PCI and the Quest for Effective Therapeutics

4 episodes
0.50 program credits
29m
MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Program Post-Test
Program Post-Test Completed
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Comments
  • Overview

    Expert faculty discuss the critical role of cardiac and inflammatory biomarkers in assessing myocardial damage, predicting risk, and monitoring treatment response. The program also explores emerging therapeutic strategies aimed at mitigating ischemia-reperfusion injury (IRI) and reducing the risk of adverse cardiovascular events. Join Drs. Manesh Patel and Deepak Bhatt as they address the long-term consequences of IRI, including the development of heart failure and increased cardiovascular mortality. By providing a comprehensive overview of IRI, this program aims to enhance understanding and inform clinical practice.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty: 
    Deepak L. Bhatt, MD, MPH
    Director, Mount Sinai Fuster Heart Hospital
    Dr. Valentin Fuster Professor of Cardiovascular Medicine
    Icahn School of Medicine at Mount Sinai
    New York, NY

    Dr. Bhatt has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Angiowave, Bayer, Boehringer Ingelheim Pharmaceuticals, Inc., CellProthera, Cereno Scientific, GlaxoSmithKline, Hims & Hers Health, Inc., Janssen Biotech, Inc., Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio Pharmaceuticals, Inc., PLx Pharma, SFJ Pharmaceuticals, Stasys Medical Corporation, Youngene Therapeutics
    Contracted Research: 89Bio, Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam Pharmaceuticals, Inc, Amarin Corporation plc, Amgen Inc., AstraZeneca Pharmaceuticals LP, Bayer, Beren, Biotronik, Boehringer Ingelheim Pharmaceuticals, Inc., Boston Scientific, Bristol Myers Squibb Company, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor Pharma, Inc., Cleerly, CSI, CSL Behring, Eisai Co., Ltd., Endotronix, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., Ischemix, Inc., Janssen Biotech, Inc., Javelin, Lexicon Pharmaceuticals, Inc., Lilly, Medtronic, Inc., Merck, Moderna, Inc., MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka Pharmaceutical Co., Ltd., Owkin, Pfizer, Inc., PhaseBio Pharmaceuticals, Inc., Philips, PLx Pharma, Recardio, Regeneron Pharmaceuticals, Inc., Roche, Sanofi, SpectraWAVE, Stasys Medical Corporation, Synaptics, The Medicines Company, Vascular Solutions, Youngene Therapeutics
    Patent Beneficiary: Lexicon Pharmaceuticals, Sotagliflozin
    Stock Options: Angiowave, Bristol Myers Squibb Company

    Manesh R. Patel, MD 
    Chief, Division of Cardiology
    Co-Director Duke Heart Center
    Duke Clinical Research Institute, Duke University
    Durham, NC

    Dr. Patel has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Bayer, Janssen, Novartis
    Contracted Research: AstraZeneca, Bayer, Janssen, Mytomy, Procyrion

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Mario P. Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the key pathophysiological mechanisms of ischemic-reperfusion injury (IRI) in patients with myocardial infarction following percutaneous coronary intervention (PCI)
    • Analyze the role of IRI in the development of subsequent heart failure and increased cardiovascular mortality in patients with ST-segment elevation myocardial infarction (STEMI) after PCI
    • Evaluate the efficacy and safety of emerging therapies in potentially limiting IRI and reducing the risk of adverse cardiovascular events in patients undergoing PCI for STEMI
  • Target Audience

    This activity has been designed to meet the educational needs of cardiologists, primary care physicians, emergency medicine and endocrinologists/lipid specialists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with IRI. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 contact hours/0.05 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is UAN JA0006235-0000-24-106-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME, LLC employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Commercial Support

    This activity is supported by an independent educational grant from Faraday Pharmaceuticals, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of TotalCME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule4 Nov 2024